The use of nonrandomized evidence to estimate treatment effects in health technology assessment

Summary

Nonrandomized studies are increasingly being used to inform health technology assessment. However, limited guidance exists from health technology assessment bodies on expectations around evidence quality and study conduct.

In this White Paper, authors affiliated with  the National Institute for Health and Care Excellence (Manchester, UK), London School of Economics and Political Science (London, UK), Università Cattolica del Sacro Cuore (Rome, Italy), University of Perugia (Italy), Andalusian School of Public Health (Granada, Spain), University of Edinburgh (UK) and the Health Technology Assessment Area (Sevilla, Spain) detail recommendations to support the appropriate use of nonrandomized evidence.